CA2667788A1 - Anti-infectieux specifiques de staphylococcus aureus - Google Patents

Anti-infectieux specifiques de staphylococcus aureus Download PDF

Info

Publication number
CA2667788A1
CA2667788A1 CA002667788A CA2667788A CA2667788A1 CA 2667788 A1 CA2667788 A1 CA 2667788A1 CA 002667788 A CA002667788 A CA 002667788A CA 2667788 A CA2667788 A CA 2667788A CA 2667788 A1 CA2667788 A1 CA 2667788A1
Authority
CA
Canada
Prior art keywords
polypeptide
isd
neat domain
isda
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002667788A
Other languages
English (en)
Inventor
Jason C. Grigg
David E. Heinrichs
Michael E. P. Murphy
Christie Vermeiren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Western Ontario filed Critical University of Western Ontario
Publication of CA2667788A1 publication Critical patent/CA2667788A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
CA002667788A 2006-10-30 2007-10-30 Anti-infectieux specifiques de staphylococcus aureus Abandoned CA2667788A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86355006P 2006-10-30 2006-10-30
US60/863,550 2006-10-30
PCT/IB2007/004635 WO2008152447A2 (fr) 2006-10-30 2007-10-30 Anti-infectieux spécifiques de staphylococcus aureus

Publications (1)

Publication Number Publication Date
CA2667788A1 true CA2667788A1 (fr) 2008-12-18

Family

ID=40130253

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002667788A Abandoned CA2667788A1 (fr) 2006-10-30 2007-10-30 Anti-infectieux specifiques de staphylococcus aureus

Country Status (2)

Country Link
CA (1) CA2667788A1 (fr)
WO (1) WO2008152447A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029831A1 (fr) 2007-08-31 2009-03-05 University Of Chicago Procédés et compositions associées pour immuniser contre des maladies et des états staphylococciques des poumons
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2010014304A1 (fr) 2008-07-29 2010-02-04 University Of Chicago Compositions et procédés apparentés à des protéines de bactérie staphylococcique
HUE057713T2 (hu) 2009-04-03 2022-05-28 Univ Chicago A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek
EP3263128A3 (fr) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions pour l'immunisation contre staphylococcus aureus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
EP3199177A1 (fr) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8
CA3133182A1 (fr) 2010-03-17 2011-09-22 Socpra Sciences Et Genie, S.E.C. Composants de vaccin bacterien provenant du staphylocoque dore et leurs utilisations
WO2012003474A2 (fr) 2010-07-02 2012-01-05 The University Of Chicago Compositions et méthodes associées à des variants de protéine a (spa)
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013030378A1 (fr) 2011-09-01 2013-03-07 Novartis Ag Formulations à adjuvant d'antigènes de staphilococcus aureus
SG11201503232TA (en) * 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
EP3529260A4 (fr) 2016-10-21 2020-12-16 SOCPRA - Sciences et Génie s.e.c. Constructions de vaccin et leurs utilisations contre des infections par staphylococcus
CN114540517B (zh) * 2022-03-08 2023-05-23 河南中检食安生物科技有限公司 闭管恒温变色检测金黄色葡萄球菌的lamp检测引物组、试剂盒及检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070085457A (ko) * 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 ＩｓｄＡ, ＩｓｄＢ, 및 ＩｓｄＣ 기재 백신,조성물 및 방법

Also Published As

Publication number Publication date
WO2008152447A3 (fr) 2011-03-03
WO2008152447A2 (fr) 2008-12-18

Similar Documents

Publication Publication Date Title
CA2667788A1 (fr) Anti-infectieux specifiques de staphylococcus aureus
AU2005310981A1 (en) Vaccines, compositions and methods based on Staphylococcus aureus iron-regulated surface determinants IsdA, IsdB, and IsdC
Grigg et al. Haem recognition by a Staphylococcus aureus NEAT domain
WO2016197071A1 (fr) Compositions et procédés en rapport avec des agents biologiques antistaphylococciques
Krishnan et al. Structure of Streptococcus agalactiae tip pilin GBS104: a model for GBS pili assembly and host interactions
US20080050361A1 (en) Staphylococcus aureas specific anti-infectives
Makthal et al. Structural and functional analysis of RopB: a major virulence regulator in S treptococcus pyogenes
Kuhn et al. Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP
US20050220788A1 (en) Use of molecules which interact with the haptoglobin receptor ligand binding
CA2871152A1 (fr) Ipc: a61k 39/395, a61p 31/04, c07k 14/705 procedes de traitement et de prevention d'infections a staphylococcus aureus et de pathologies associees
DK1784220T3 (en) BACTERIAL OBJECTIVES TO ACHIEVE IRON
Hofmans et al. Ses proteins as possible targets for vaccine development against Staphylococcus epidermidis infections
Hughes et al. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59
US8729013B2 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
CA2576643A1 (fr) Essais de criblage d'inhibiteurs d'un siderophore de staphylococcus aureus
US20100129349A1 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
US20070292873A1 (en) Bacterial iron acquisition targets
SADONES et al. Investigation of cross-opsonic effect leads to the discovery of PPIase-domain containing protein vaccine target to prevent infections by Gram-positive ESKAPE pathogens
Manne Structural Studies Of Some Proteins Responsible For Bacterial Pathogenesis
Garrigues Borrelia burgdorferi ErpB and ErpQ Inhibit C1 Complex of the Classical Pathway of Complement Through a Novel Mechanism
Alanko et al. Isolation and functional analysis of phage‐displayed antibody fragments targeting the staphylococcal superantigen‐like proteins
Mans Translocation and Function of Akt in the Mitochondria
Isaac Functional Characterization of Regulators of Bacterial Pathogenicity and Metabolism
CA2433308A1 (fr) Compositions et methodes mettant en oeuvre un gene essentiel de staphylococcus aureus et proteine codee staau r4 associee

Legal Events

Date Code Title Description
FZDE Dead